Gyre Therapeutics (GYRE) Minority Interest (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Minority Interest of $35.7 million for Q1 2026, down 1.39% year-over-year from $36.2 million in Q1 2025, and down 1.59% quarter-over-quarter from $36.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Minority Interest (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Minority Interest for 5 consecutive years, with $35.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Minority Interest fell 1.39% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (down 1.39% YoY), while the FY2025 annual figure was $36.3 million, up 3.33% from the prior year.
- Minority Interest retreated to $35.7 million in Q1 2026 per GYRE's latest filing, from $36.3 million in the prior quarter.
- Across five years, Minority Interest topped out at $37.4 million in Q2 2025 and bottomed at $29.7 million in Q4 2022.
- Historically, Minority Interest has averaged $34.2 million across 5 years, with a median of $35.3 million in 2024.
- Annual changes were most pronounced in 2024 — Minority Interest climbed 17.82% — and 2026, when it declined 1.39%.
- Gyre Therapeutics' Minority Interest stood at $29.7 million in 2022, then advanced by 0.28% to $29.8 million in 2023, then climbed by 17.82% to $35.1 million in 2024, then grew by 3.33% to $36.3 million in 2025, then declined by 1.59% to $35.7 million in 2026.
- Business Quant data shows GYRE's Minority Interest at $35.7 million in Q1 2026, $36.3 million in Q4 2025, and $35.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.56 Mn |
| Mar 31, 2026 | 35.68 Mn |
| Dec 31, 2025 | 36.25 Mn |
| Sep 30, 2025 | 35.50 Mn |
| Jun 30, 2025 | 37.42 Mn |
| Mar 31, 2025 | 36.18 Mn |
| Dec 31, 2024 | 35.08 Mn |
| Sep 30, 2024 | 35.30 Mn |
| Jun 30, 2024 | 33.00 Mn |
| Mar 31, 2024 | 32.13 Mn |
| Dec 31, 2023 | 29.78 Mn |
| Dec 31, 2022 | 29.70 Mn |